^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NY-ESO-1 TCR-T cell therapy

    i
    Other names: NY-ESO-1 TCR-T cell therapy, TCR engineered T cell therapy, NY-ESO-1 TCR-T triple knockout TCR therapy, NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells, NYCE T Cells
    Associations
    News
    Trials
    Company:
    Gilead
    Drug class:
    PD1 inhibitor, TCR modulator, NY ESO 1 inhibitor
    Related drugs:
    Associations
    News
    Trials